Search results for "Survival"

showing 10 items of 3291 documents

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

2010

On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia.Treatment-naive, physically fit patients (aged 30-81 years) with CD20-positive chronic lymphocytic leukaemia were randomly assigned in a one-to-one ratio to receive six courses of intravenous fludarabine (25 mg/m(2) per day) and cyclophosphamide (250 mg/m(2) per day) for the first 3 days of each 28-day treatment course with or without rituximab (375 mg/m(2) on day 0 of first course, and 500 mg/m(2) on da…

AdultMalemedicine.medical_specialtyNeutropeniaFCR RegimenKaplan-Meier EstimateOfatumumabSeverity of Illness IndexGastroenterologyDisease-Free SurvivalDrug Administration ScheduleAntibodies Monoclonal Murine-Derivedchemistry.chemical_compoundChemoimmunotherapyObinutuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansImmunologic FactorsMedicineCyclophosphamideAgedAged 80 and overbusiness.industryIncidenceAntibodies MonoclonalLeukopeniaGeneral MedicineMiddle AgedLeukemia Lymphocytic Chronic B-CellSurgeryFludarabineTreatment OutcomechemistryDisease ProgressionFemaleRituximabRefractory Chronic Lymphocytic LeukemiaRituximabbusinessVidarabineUntreated Chronic Lymphocytic Leukemiamedicine.drug
researchProduct

Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma

2000

The efficacy of oxaliplatin combined with high-dose 5-fluorouracil (5-FU) and folinic acid (FA) as an outpatient salvage treatment for patients with metastasized colorectal cancer was retrospectively analyzed in one center. Tumor progression had occurred for the majority of patients during two regimens (n = 11) otherwise during one (n = 1) regimen of prior 5-FU-based chemotherapy, which had been applied in a standardized sequential fashion. As third-line therapy oxaliplatin was infused intravenously over 2 h at a dose of 60 mg/m2 prior to a 2-h infusion of FA (500 mg/m2). 5-FU (2,600 mg/m2) was subsequently given over 24 h. A favorable response was observed in 9/12 (75%) of the heavily pret…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsNauseaColorectal cancermedicine.medical_treatmentLeucovorinGastroenterologyDisease-Free SurvivalDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineInfusions IntravenousAgedNeoplasm StagingRetrospective StudiesSalvage TherapyChemotherapyDose-Response Relationship Drugbusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseOxaliplatinOxaliplatinRegimenFluorouracilColon neoplasmFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

Selective approach to the treatment of oesophageal cancer

1996

Abstract Between September 1985 and December 1994, 322 patients with oesophageal cancer were treated. Of the 190 patients who underwent operation, 173 had an oesophageal resection; in 124 this was performed as an abdominothoracic resection and in 49 by the transhiatal approach. The assessment of radicality after histological examination revealed a curative (R0) resection in 121 patients (70 per cent) and a palliative (R1-R2) resection in 52 (30 per cent). Prognosis was correlated with the extent of mediastinal lymph node dissection. In 77 patients with stage pT1–3 pN0–1 pM0 the 5-year survival rate was 40 per cent after abdominothoracic resection with two-field lymph node dissection and zer…

AdultMalemedicine.medical_specialtyPalliative careEsophageal Neoplasmsmedicine.medical_treatmentAdenocarcinomamedicineCarcinomaHumansLymph nodeSurvival rateAgedRetrospective StudiesAged 80 and overbusiness.industryMiddle AgedEsophageal cancerPrognosismedicine.diseaseSurvival AnalysisSurgeryDissectionmedicine.anatomical_structureLymphatic MetastasisMediastinal lymph nodeCarcinoma Squamous CellLymph Node ExcisionFemaleSurgeryLymphadenectomybusinessBritish Journal of Surgery
researchProduct

Pattern and characteristics of advanced cancer patients admitted to hospices in Italy

2013

Abstract The aim of this multicenter study was to assess the pattern and the characteristics of advanced cancer patients admitted to hospices. A consecutive sample of patients admitted in a period of 6 months was taken into consideration. Two hundred thirty-six patients admitted to hospices were consecutively assessed. Ninety-six percent of patients were admitted in acute hospital in the previous 3 months, with a mean time spent in hospital of 34.5 days, and 47 % of patients had received chemotherapy the month before hospice admission. Thirty-four percent of patients for whom data were available had significant persistent pain, and 44 % of them presented episodes of breakthrough pain. Sixty…

AdultMalemedicine.medical_specialtyPalliative caredescriptive studyPain medicineSettore MED/42 - Igiene Generale E ApplicataFentanyladvanced cancer patientNeoplasmsOutcome Assessment Health CaremedicineHumansProspective StudiesIntensive care medicineProspective cohort studySurvival analysisAgedadvanced cancer patients; hospice; descriptive studyAged 80 and overTerminal CareMarital Statusbusiness.industryNursing researchPalliative CareHospicesLength of StayMiddle AgedSurvival AnalysisAnalgesics OpioidLogistic ModelsOncologyOpioidItalyhospiceEmergency medicineMarital statusFemalebusinessmedicine.drug
researchProduct

Long term follow up of patients with chronic pancreatitis and pancreatic stones treated with extracorporeal shock wave lithotripsy

1999

BACKGROUNDThere have been conflicting reports as to whether pancreatic ductal drainage achieved by endoscopy and lithotripsy improves the clinical outcome of patients with chronic pancreatitis.AIMSTo determine the clinical outcome in patients with chronic pancreatitis who received extracorporeal shock wave lithotripsy (ESWL), and were followed up for two to eight years.METHODSEighty patients with severe chronic pancreatitis and endoscopically unretrievable obstructive stones underwent ESWL with a piezoelectric lithotripter between 1989 and 1996. Clinical status, relief of symptoms, further endoscopic or surgical interventions, and mortality were defined.RESULTSForty three (54%) patients wer…

AdultMalemedicine.medical_specialtyPancreatic diseaseAdolescentmedicine.medical_treatmentLithotripsyCalculiArticleLithotripsyPancreatic cancermedicineHumansPancreatic Duct StoneSurvival ratebusiness.industryGastroenterologyPancreatic DiseasesMiddle Agedmedicine.diseaseExtracorporeal shock wave lithotripsySurgeryRadiographySurvival RateTreatment Outcomemedicine.anatomical_structurePancreatitisChronic DiseasePancreatitisFemalePancreasbusinessFollow-Up StudiesGut
researchProduct

Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis.

2011

Background. Liver transplantation (LT) has been accepted as a treatment in selected cases of neuroendocrine tumors (NETs) with hepatic metastases. Patients and Methods. A systematic review of the literature was conducted to evaluate long-term patient survival in the instances of LT for pancreatic NET. Univariate and multivariate regression analyses and survival analysis were performed. Results. Fifty-three clinical studies were screened. Data from 20 studies encompassing 89 transplanted patients were included in the study. Most primary tumors were endocrine pancreatic tumors (n = 69), with gastrinomas representing the most frequent diagnosis (n = 21). There were 61 functioning pancreatic NE…

AdultMalemedicine.medical_specialtyPancreatic diseaseAdolescentmedicine.medical_treatmentPopulationMedizinLiver transplantationNeuroendocrine tumorsGastroenterologyYoung AdultPancreatic tumorInternal medicineCarcinomamedicineHumanseducationChildSurvival analysisRetrospective StudiesTransplantationeducation.field_of_studybusiness.industryLiver NeoplasmsCancerMiddle Agedmedicine.diseasePrognosisSurvival AnalysisCarcinoma NeuroendocrineLiver TransplantationPancreatic NeoplasmsFemalebusinessTransplantation
researchProduct

Recent Trends in Survival of Patients With Pancreatic Cancer in Germany and the United States

2016

Objectives Survival improvement for pancreatic cancer has not been observed in the last 4 decades. We report the most up-to-date population-based relative survival (RS) estimates and recent trends in Germany and the United States. Methods Data for patients diagnosed in 1997 to 2010 and followed up to 2010 were drawn from 12 population-based German cancer registries and the US SEER (Surveillance, Epidemiology and End Results) 13 registries database. Using period analysis, 5-year RS for 2007 to 2010 was derived. Model-based period analysis was used to assess 5-year RS time trends, 2002-2010. Results In total 28,977 (Germany) and 34,793 (United States) patients aged 15 to 74 years were analyze…

AdultMalemedicine.medical_specialtyPathologyAdolescentEndocrinology Diabetes and MetabolismPopulationYoung Adult03 medical and health sciencesAge DistributionSex Factors0302 clinical medicineEndocrinologyGermanyPancreatic cancerEpidemiologyInternal MedicineHumansMedicineRegistriesYoung adulteducationSurvival analysisAgedNeoplasm StagingAged 80 and overeducation.field_of_studyHepatologyRelative survivalbusiness.industryAge FactorsCancerMiddle AgedPrognosismedicine.diseaseSurvival AnalysisUnited StatesPancreatic NeoplasmsSurvival Rate030220 oncology & carcinogenesisPeriod AnalysisFemale030211 gastroenterology & hepatologybusinessSEER ProgramDemographyPancreas
researchProduct

Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome

2003

Background: High serum levels of soluble intercellular adhesion molecule-1(s-ICAM-1/s-CD54) have been associated with adverse clinical features and poor outcome in chronic lymphocytic leukemia, Hodgkin’s disease and non-Hodgkin’s lymphoma, but their value in the different subtypes of non-Hodgkin’s lymphoma has not been well addressed. Patients and methods: Our aim was to study the serum levels of s-ICAM-1 in diffuse large B-cell lymphoma (DLBCL) and to correlate them with clinical characteristics and outcome. We analyzed the serum levels of s-ICAM-1 in a series of 55 patients with DLBCL diagnosed in a single institution. s-ICAM-1 levels were quantified by an immunoenzymatic assay. Median ag…

AdultMalemedicine.medical_specialtyPathologyLymphoma B-CellChronic lymphocytic leukemiaGastroenterologyImmunoenzyme TechniquesInternational Prognostic IndexRisk Factorshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansSurvival analysisAgedAged 80 and overL-Lactate DehydrogenaseBeta-2 microglobulinbusiness.industryLymphoma Non-HodgkinLarge-cell lymphomaHematologyMiddle AgedIntercellular Adhesion Molecule-1Prognosismedicine.diseaseSurvival AnalysisLymphomaTreatment OutcomeOncologyB symptomsCase-Control StudiesLymphatic MetastasisDisease ProgressionFemaleLymphoma Large B-Cell Diffusemedicine.symptombusinessDiffuse large B-cell lymphomaAnnals of Oncology
researchProduct

Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century.

2013

Summary Treatment for Hodgkin lymphoma (HL) is more aggressive in Germany than in the United States (US) and differences in treatment may lead to differences in population level survival. Patients diagnosed with HL in 11 German states in 1997–2006 were included in the analyses and were compared to similar analyses from patients in the Surveillance, Epidemiology, and End Results database in the US. Period analysis was used to calculate 5-year relative survival for the time period of 2002–2006 overall and by gender, age and histology. Overall 5-year relative survival for patients with HL in Germany was 84·3%, compared to 80·6% for the US. Survival was highest in patients aged 15–29 years at 9…

AdultMalemedicine.medical_specialtyPediatricsPopulation levelPopulationLate toxicityOlder patientsGermanyEpidemiologyMedicineHumanseducationeducation.field_of_studyRelative survivalbusiness.industryAge FactorsHematologyMiddle AgedHodgkin DiseaseSurvival AnalysisSurvival RateHodgkin lymphomaPeriod AnalysisFemalebusinessBritish journal of haematology
researchProduct

A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagoga…

2009

The combination of irinotecan with 5-fluorouracil demonstrates efficacy with tolerable safety in the first-line treatment of metastatic gastroesophageal cancer (mGC). This randomized phase II trial compared for the first time capecitabine with irinotecan or cisplatin in this setting.Patients were randomly assigned to receive 3-week cycles of capecitabine 1000 mg/m(2), twice daily for 14 days, with on day 1 either irinotecan 250 mg/m(2) (XI) or cisplatin 80 mg/m(2) (XP). The primary end point was overall response rate (ORR) and secondary end points included progression-free survival (PFS), overall survival (OS) and safety.Of 118 patients recruited, 112 were eligible for safety analysis and 1…

AdultMalemedicine.medical_specialtyPhases of clinical researchKaplan-Meier EstimateAdenocarcinomaIrinotecanDeoxycytidineGastroenterologyCapecitabineStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalStomach cancerCapecitabineAgedbusiness.industryCombination chemotherapyHematologyMiddle Agedmedicine.diseaseSurgeryIrinotecanRegimenOncologyFluorouracilCamptothecinFemaleEsophagogastric JunctionFluorouracilCisplatinbusinessmedicine.drugAnnals of Oncology
researchProduct